Organon shares climbed ~28% after a report that Sun Pharmaceutical is set to make a $12B offer, following a prior 8% gain on related speculation. Sun called the report "speculative." The stock's extreme reaction to successive days of M&A speculation indicates the market assigns a high probability to a deal, with reports claiming detailed due diligence has been completed. WATCH due to high, event-driven volatility centered on a potential takeover, where the outcome is binary and dependent on a formal offer materializing. The deal fails to materialize, causing the speculative premium to collapse.